Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
BMJ Open. 2019 Jun 14;9(6):e028156. doi: 10.1136/bmjopen-2018-028156.
Current evidence supporting the utility of endoscopic ultrasound-guided biliary drainage (EUS-BD) as a first-line treatment option for malignant biliary obstruction (MBO) is limited. We plan to provide a systematic review and meta-analysis to compare the performance of EUS-BD and endoscopic retrograde cholangiopancreatography-guided biliary drainage (ERCP-BD) as primary palliation of MBO.
Randomised controlled trials evaluating EUS-BD versus ERCP-BD in primary drainage of MBO will be searched in MEDLINE, EMBASE, Web of Science, the Cochrane Library, ClinicalTrials.gov and Google Scholar, from database inception to 31 October 2018. Data on study design, participant characteristics, intervention details and outcomes will be extracted. Primary outcomes to be assessed are technical and clinical success. Secondary outcomes include adverse events, stent patency, stent dysfunction, reinterventions, procedure duration and overall survival. Study quality will be assessed using the Cochrane Risk of Bias Tool. Meta-analysis will be performed using RevMan V.5.3 statistical software. Data will be combined with a random effect model. The results will be presented as a risk ratio for dichotomous data, weighted mean difference for continuous data and HR for time-to-event data. Publication bias will be visualised using funnel plots.
This study will not use primary data, and therefore, formal ethical approval is not required. The findings will be disseminated through peer-reviewed journals and committee conferences.
CRD42018117040.
目前,支持内镜超声引导下胆道引流术(EUS-BD)作为恶性胆道梗阻(MBO)一线治疗选择的证据有限。我们计划进行系统评价和荟萃分析,以比较 EUS-BD 和内镜逆行胰胆管造影引导下胆道引流术(ERCP-BD)作为 MBO 初步姑息治疗的效果。
将在 MEDLINE、EMBASE、Web of Science、Cochrane 图书馆、ClinicalTrials.gov 和 Google Scholar 中搜索评估 EUS-BD 与 ERCP-BD 用于 MBO 一线引流的随机对照试验,检索时间截至 2018 年 10 月 31 日。将提取研究设计、参与者特征、干预措施细节和结局的数据。主要结局评估为技术和临床成功率。次要结局包括不良事件、支架通畅性、支架功能障碍、再干预、操作时间和总生存。使用 Cochrane 偏倚风险工具评估研究质量。使用 RevMan V.5.3 统计软件进行荟萃分析。将使用随机效应模型合并数据。结果将以二分类数据的风险比、连续数据的加权均数差和时间到事件数据的 HR 表示。使用漏斗图可视化发表偏倚。
本研究不使用原始数据,因此不需要正式的伦理批准。研究结果将通过同行评议期刊和委员会会议进行传播。
PROSPERO 注册号:CRD42018117040。